ישראל -
עברית -
Ministry of Health
קלריטון
fischer pharmaceuticals ltd - benzalkonium chloride - טיפות עיניים - benzalkonium chloride 0.01 % - benzalkonium - benzalkonium - for rinsing and soothing the eyes against irritation due to various causes such as: dust, smoke, plants etc. for first aid use in helping remove a foreign body from the eye.
ישראל -
עברית -
Ministry of Health
טיג'ל ג'ל
rafa laboratories ltd - cetalkonium chloride; choline salicylate - ג'ל - cetalkonium chloride 0.01 %w/w; choline salicylate 8.7 %w/w - choline salicylate - choline salicylate - as an antiseptic and local pain reliever for mouth ulcers, teething pain, denture irritation, and cold sores.
ישראל -
עברית -
Ministry of Health
ביבי גאם
rafa laboratories ltd - cetalkonium chloride; choline salicylate - ג'ל - cetalkonium chloride 0.01 %w/w; choline salicylate 8.7 %w/w - choline salicylate - choline salicylate - as an antiseptic and local pain reliever for mouth ulcers, teething pain, denture irritation, and cold sores.
ישראל -
עברית -
Ministry of Health
אקריזקס
trupharm marketing 1985 ltd. - dermatophagoides farina; dermatophagoides pteronyssinus - טבליה - dermatophagoides pteronyssinus 6 sq-hdm; dermatophagoides farina 6 sq-hdm - house dust
ישראל -
עברית -
Ministry of Health
אמולסידרם
trupharm marketing 1985 ltd. - benzalkonium chloride 0.5 %w/v; isopropyl myristate 25 %w/v - emulsion - benzalkonium - for the treatment of dry skin conditions especially associated with eczema, ichtyosis or xeroderma. it permits rehydratation of the keratin.
ישראל -
עברית -
Ministry of Health
walkaide system - functional electrical stimulation (fes) for treatment of foot drop
סטרייד אורטופדיה בע"מ - מומחה - מערכת הווקאייד - מכשיר גירוי חשמלי תפקודי לטיפול בצניחת כף רגל
ישראל -
עברית -
Ministry of Health
אקסטביה
novartis pharma services ag - interferon beta 1b 0.3 mg - powder and solvent for solution for injection - interferon beta-1b - extavia is indicated for the treatment of:• for use in relapsing-remitting and relapsing-progressive multiple sclerosis. it is designated for ambulatory patients who meet criteria for clinically definite and for laboratory supported definite ms, and who have experienced at least two exacerbations over the last two years.extavia reduces the frequency of clinical exacerbations.in secondary progressive multiple sclerosis extavia is indicated for slowing progression of disease and for the reduction of frequency of clinical relapses. compared with placebo, patients receiving extavia showed a statistically significant delay in time to progression of multiple sclerosis. the treatment effect occurred in patients with and without relapses and at all levels of disability investigated (patients with mild disease and those unable to walk were not studied). patients receiving extavia also showed a statistically significant delay in the time to become wheelchair-bound when compared with placebo. see also section 5.1 “pharm
ישראל -
עברית -
Ministry of Health
קסאלקורי 200 מג
pfizer pharmaceuticals israel ltd - crizotinib - קפסולות - crizotinib 200 mg - crizotinib - crizotinib - xalkori is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (nsclc) that is anaplastic lymphoma kinase (alk)-positive.